Anna Obenauf
@obenaufa
Group leader @IMPvienna, trained @sloan_kettering working on #cancer #tumorimmunology #resistance. Mentor. Mum. Views are my own. Also: @obenaufa.bsky.social
Thrilled to share that our paper nature.com/articles/s4158… is featured in a fantastic Nature News & Views piece by @ThomasTueting! 🎉 Grateful for the spotlight on our research and its impact on understanding cancer immunology. nature.com/articles/d4158… 👀👉 rdcu.be/d3cRz
Prostaglandins made by tumor cells reprograms immune cells, leading to an interesting clinical hypothesis. nature.com/articles/d4158…
Big congratulations to all the newly elected @embo.org Members! A special shoutout to @IMPvienna #ClemensPlaschka @plaschka_lab for this well-deserved recognition. embo.org/press-releases…
👩🔬 @jentoft_ida won a Birnstiel Award for her outstanding doctoral research in 2023. Do you know an exceptional PhD student? The Birnstiel Award has an open call! 📅 Nominate by 30 June: imp.ac.at/achievements/b… @viennabiocenter
Honored to organize with Drs. Tom Marron, @MellmanIra @peters_solange the 2026 @KeystoneSymp #CancerImmunotherapy: Mechanisms, Clinical Advances and Combinations, this October! Join us in Québec! keysym.us/KSCancerImmune… #KSCancerImmune26
1/3💡If you are looking for a postdoc position in transformative translational research, join our team! We are looking for a motivated postdoc to work on RNA-mediated in vivo reprogramming of cancer cells into dendritic cells.
🎉 Today, we gathered online for the #AdaptMet Kick-Off Meeting! A fantastic start to this journey, bringing together top researchers & partners to train the next generation of metastasis experts. Exciting discussions & collaborations ahead—stay tuned! 🔬✨ #CancerResearch
Congrats @EllingUlrich!
CRISPR-StAR enables high-resolution genetic screening in complex in vivo models go.nature.com/4giANvD
I am so grateful to have had the opportunity of recruiting @guillemxtivill through the @evomet_itn program! He is hungry for discovery, innovative and a wonderful colleague! His work with @AnaisElewaut culminated in a recent paper nature.com/articles/s4158… with more to come.
Guillem Estivill, researcher at IMP
Our AI for virtual cells article is now published in @CellCellPress with lots of amazing co-authors who gathered with us at @cziscience and @_bunnech, Aviv, @Prof_Lundberg , @jure , and @StephenQuake sciencedirect.com/science/articl…
What a joy it has been to share a bit of life with Dr. @AnaisElewaut over the past years. So proud of her and @guillemxtivill work providing insights into anti-tumor immunity and their brand-new paper out in @Nature! 🎉👏 nature.com/articles/s4158…
Congrats to Anais Elewaut PhD (@obenaufa lab), who recently defended her thesis: 'Cancer cell impair monocyte-mediated intratumoral T cell stimulation to evade immunity' - Well done Anais! 🥂🍾 @univienna @IMPvienna @IMBA_Vienna @gmivienna @MaxPerutzLabs
Two PhD defenses within a week! Congratulations Shona! It has been fantastic working with you!
Congrats to Shona Cronin PhD (@obenaufa lab), who recently defended her thesis: 'Dissecting the clonal dynamics and mechanisms contributing to immunotherapy resistance' - Well done Shona! 🥂🍾 @univienna @IMPvienna @IMBA_Vienna @gmivienna @MaxPerutzLabs
DC5 will research molecular mechanisms of immune responses and evasion in metastatic colonisation under the supervision of Anna Christina Obenauf at the Institute of Molecular Pathology
Sebastian Carotta at Boehringer Ingelheim will oversee DC12's work on the induction of immunogenic cell death in cancer cells to initiate a systemic antitumor immune response